Results of the Combined General Shareholders’ Meeting held on June 29 2018
03/07/2018 – The voting details for each resolution are available in the Investor Relations section of the website.
03/07/2018 – The voting details for each resolution are available in the Investor Relations section of the website.
03/07/2018 – Presentation of the current situation and future prospects.
19/06/2018 – AB Science expects study to be completed in 2019.
28/05/2018 – AB Science is evaluating the possibility to resubmit the application based on the final results from study AB10015.
30/04/2018 – AB Science reports on its annual financials as of 31 December 2017 and provides an update on its activities.
19/04/2018 – AB Science will provide additional data through a reexamination procedure
04/01/2018 – Additionally, the IDMC did not report any safety concern with masitinib in the study population.
European Hematology Association June 2017 22/06/2017 – MASITINIB FOR TREATMENT OF SEVERELY SYMPTOMATIC INDOLENT SYSTEMIC MASTOCYTOSIS: ADDITIONAL EFFICACY ANALYSES FROM THE RANDOMIZED, PLACEBOCONTROLLED, PHASE 3 STUDY
Abstract O. Hermine Industry’s Perspective 2016 01/07/2016 – Development of masitinib, a novel tyrosine kinase inhibitor and immunotherapeutic, for the treatment of peripheral T-cell lymphoma